Home » Increased Focus on Postapproval Trials Prompts Guidance
Increased Focus on Postapproval Trials Prompts Guidance
September 10, 2007
As part of increased agency attention to postapproval studies that may be required for product approval, the U.S. Food and Drug Administration (FDA) has issued a new guidance addressing the study reports that manufacturers must submit at regular intervals.
To View This Article:
Subscribe To International Medical Device Regulatory Monitor